NCT00786474View on ClinicalTrials.gov

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,884

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Arterial Thromboembolic EventsAtrial Fibrillation
Interventions
DRUG

Placebo

Normal saline solution, dosage determined by weight, self-administered by patient twice a day

DRUG

Dalteparin

Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day

Trial Locations (1)

27715

Duke Clinical Research Institute, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Duke University

OTHER